Phase III Study to Evaluate Efficacy and Safety of HGP1207 in Patients With Pulmonary Hypertension Associated With Systolic Heart Failure
Phase of Trial: Phase III
Latest Information Update: 29 Sep 2016
At a glance
- Drugs Sildenafil (Primary)
- Indications Chronic heart failure; Pulmonary hypertension
- Focus Therapeutic Use
- Sponsors Hanmi Pharmaceutical
- 07 Jun 2017 Biomarkers information updated
- 14 Mar 2016 Planned End Date changed from 1 Feb 2015 to 1 May 2017, according to ClinicalTrials.gov record.
- 14 Mar 2016 Planned primary completion date changed from 1 Feb 2015 to 1 Mar 2017, according to ClinicalTrials.gov record.